Impact of Therapeutic Area-Specific Data Standards for Parkinson’s Disease
Share this
Related Posts
-
The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases -
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
-
Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease
-
Critical Path for Parkinson’s: Regulatory Path to Enable Targeting the Right Patients in Clinical Trials of Early Stages of Parkinson’s Disease
-
CAMD: Development of Therapeutic Area-Specific Data Standards for Brain Diseases